Neurology

Validation of MRI biomarker of white matter degeneration for ALS clinical trials: One small step




Amyotrophic lateral sclerosis (ALS) is a progressive, paralytic disorder characterized by degeneration of motor neurons in the brain and spinal cord.1 It is part of the ALS–frontotemporal dementia spectrum of disorders that dismantle systematically the behavioral-executive-motor neuronal supernetwork. Measures of strength or function have served as primary outcome measures for most ALS treatment trials.2 Advanced neuroimaging techniques offer the potential to aid in diagnosing ALS and monitoring disease progression. Diffusion tensor imaging (DTI), a robust MRI tool for in vivo analysis of white matter (WM) neuronal tracts, has been applied successfully to study ALS in cross-sectional and longitudinal single-center cohort studies.3–6 Regional reduction of DTI metrics such as fractional anisotropy (FA) has been used as a marker for axonal degeneration and myelin degradation.3,4

Source link








WordPress database error: [Error writing file '/tmp/MYGq64JP' (Errcode: 28 - No space left on device)]
SELECT SQL_CALC_FOUND_ROWS wp_posts.ID FROM wp_posts LEFT JOIN wp_term_relationships ON (wp_posts.ID = wp_term_relationships.object_id) WHERE 1=1 AND wp_posts.ID NOT IN (416037) AND ( wp_term_relationships.term_taxonomy_id IN (4) ) AND wp_posts.post_type = 'post' AND (wp_posts.post_status = 'publish') GROUP BY wp_posts.ID ORDER BY RAND() LIMIT 0, 3

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy